Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer’s Dementia after Failure to Respond to Donepezil
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveaaThis study compares the efficacy of the cholinesterase inhibitor (ChEI) galantamine on cognition in patients with mild-to-moderate Alzheimer’s dementia (AD) who were either naïve to ChEI drugs or who had failed a trial of the ChEI donepezil. MethodsaaOutpatients with AD were sequentially referred for screening and enrollment. Current outpatients who had taken donepezil for at least 6 months without demonstrated efficacy on cognition were switched to galantamine (switched group). New outpatients with no ChEI prescription history were classified as the naïve group and were given galantamine. The primary outcome measures for the betweengroup comparison were response rate on cognition at 26 and 52 weeks (categorical) and change on the Korean version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (dimensional). Secondary cognitive outcomes were measured using the subset of frontal executive function and the Korean Mini-Mental State Examination. ResultsaaSeventy outpatients were enrolled and 66 were analyzed by Intent-to-treat (ITT). There were 42 cases in the naïve group and 24 in the switched group. Response rates did not differ at 26 weeks (71.4% naïve vs. 58.3% switched; p=0.277) or at 52 weeks (59.5% naïve vs. 41.6% switched; p=0.162). No significant differences were observed in the pattern of change over the 52 weeks on the primary and secondary cognitive scales. ConclusionaaAs the efficacy of galantamine on cognition was not inferior in the switched group compared to that in the naïve group, switching ChEI drugs is clinically feasible for non-responding patients with mild-to-moderate AD.
Abstract
ObjectiveaaThis study compares the efficacy of the cholinesterase inhibitor (ChEI) galantamine on cognition in patients with mild-to-moderate Alzheimer’s dementia (AD) who were either naïve to ChEI drugs or who had failed a trial of the ChEI donepezil. MethodsaaOutpatients with AD were sequentially referred for screening and enrollment. Current outpatients who had taken donepezil for at least 6 months without demonstrated efficacy on cognition were switched to galantamine (switched group). New outpatients with no ChEI prescription history were classified as the naïve group and were given galantamine. The primary outcome measures for the betweengroup comparison were response rate on cognition at 26 and 52 weeks (categorical) and change on the Korean version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (dimensional). Secondary cognitive outcomes were measured using the subset of frontal executive function and the Korean Mini-Mental State Examination. ResultsaaSeventy outpatients were enrolled and 66 were analyzed by Intent-to-treat (ITT). There were 42 cases in the naïve group and 24 in the switched group. Response rates did not differ at 26 weeks (71.4% naïve vs. 58.3% switched; p=0.277) or at 52 weeks (59.5% naïve vs. 41.6% switched; p=0.162). No significant differences were observed in the pattern of change over the 52 weeks on the primary and secondary cognitive scales. ConclusionaaAs the efficacy of galantamine on cognition was not inferior in the switched group compared to that in the naïve group, switching ChEI drugs is clinically feasible for non-responding patients with mild-to-moderate AD.
참고문헌 (39)
- Scarpini E, "Treatment of Alzheimer’s disease : current status and new perspectives", Lancet Neurol, 2, pp.539~547 (2003)
- Burns A, "Clinical practice with anti-dementia drugs : a consensus statement from British Association for Psychopharmacology", J Psychopharmacol, 20, pp.732~755 (2006)
- Wilkinson DG, "Cholinesterase inhibitors used in the treatment of Alzheimer’s disease : the relationship between pharmacological effects and clinical efficacy", Drugs Aging, 21, pp.453~478 (2004)
- Ritchie CW, "Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease", Am J Geriatr Psychiatry, 12, pp.358~369 (2004)
- Auriacombe S, "Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil", Curr Med Res Opin, 18, pp.129~138 (2002)
- Mintzer JE, "The efficacy of galantamine in the treatment of Alzheimer’s disease : comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure", Int J Geriatr Psychiatry, 18, pp.292~297 (2003)
- Bartorelli L, "Effects of switching from an AChE inhibitor to a dual AChEBuChE inhibitor in patients with Alzheimer’s disease", Curr Med Res Opin, 21, pp.1809~1818 (2005)
- Gauthier S, "A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study", Curr Med Res Opin, 22, pp.2251~2265 (2006)
- Gauthier S, "Strategies for continued successful treatment of Alzheimer’s disease : switching cholinesterase inhibitors", Curr Med Res Opin, 19, pp.707~714 (2003)
- Farlow MR, "Pharmacokinetic profiles of current therapies for Alzheimer’s disease: implications for switching to galantamine", Clin Ther, 23(Suppl A), pp.A13~A24 (2001)
- Maelicke A, "Pharmacokinetic rationale for switching from donepezil to galantamine", Clin Ther, 23(Suppl A), pp.A8~A12 (2001)
- Raskind MA, "Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group", Neurology, 54, pp.2261~2268 (2000)
- Lyketsos CG, "Long-term outcomes of galantamine treatment in patients with Alzheimer disease", Am J Geriatr Psychiatry, 12, pp.473~482 (2004)
- Kawas CH, "Clinical trials in Alzheimer disease : debate on the use of placebo controls", Alzheimer Dis Assoc Disord, 13, pp.124~129 (1999)
- Stern RG, "A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration", Am J Psychiatry, 151, pp.390~396 (1994)
- McKhann G, "Clinical diagnosis of Alzheimer’s disease : report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
- Han C, "An adaptation of the Korean mini-mental state examination(K-MMSE)in elderly Koreans : demographic influence and population-based norms(the AGE study)", Arch Gerontol Geriatr, 47, pp.302~310 (2008)
- Lynch CA, "The clinical dementia rating sum of box score in mild dementia", Dement Geriatr Cogn Disord, 21, pp.40~43 (2006)
- Rasmusen L, "Effects of washout and doseescalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials", Clin Ther, 23(Suppl A), pp.A25~A30 (2001)
- Wilkinson DG, "Switching from donepezil to galantamine : a double-blind study of two wash-out periods", Int J Geriatr Psychiatry, 20, pp.489~491 (2005)
- Lingjaerde O, "The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients", Acta Psychiatr Scand Suppl, 334, pp.1~100 (1987)
- Winblad B, "Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success?", Int J Geriatr Psychiatry, 16, pp.653~666 (2001)
- Erkinjuntti T, "Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease : a randomised trial", Lancet, 359, pp.1283~1290 (2002)
- Rosen WG, "A new rating scale for Alzheimer’s disease", Am J Psychiatry, 141, pp.1356~1364 (1984)
- Youn JC, "Development of the Korean version of Alzheimer’s Disease Assessment Scale(ADAS-K)", Int J Geriatr Psychiatry, 17, pp.797~803 (2002)
- Mohs RC, "Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study", Alzheimer Dis Assoc Disord, 11(Suppl 2), pp.S13~S21 (1997)
- Seo EH, "A normative study of the Trail Making Test in Korean elders", Int J Geriatr Psychiatry, 21, pp.844~852 (2006)
- 송호정, "한국 노인의 숫자폭 및 시공간폭 검사 표준화 연구", Korean Journal of Clinical Psychology, 25(2), pp.505~532 (2006), 한국임상심리학회
- Lee JH, "A normative study of the Korean version of Controlled Oral Word Association Test(COWAT)in the elderly", Korean J Clin Psychol, 19, pp.385~392 (2000)
- Kang YW, "A validity study on the Korean Mini-Mental State Examination(K-MMSE)in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
- Folstein MF, "“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician", J Psychiatr Res, 12, pp.189~198 (1975)
- Tariot PN, "A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group", Neurology, 54, pp.2269~2276 (2000)
- Takeda A, "A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease", Int J Geriatr Psychiatry, 21, pp.17~28 (2006)
- Wilcock G, "A longterm comparison of galantamine and donepezil in the treatment of Alzheimer’s disease", Drugs Aging, 20, pp.777~789 (2003)
- Jones RW, "A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer’s disease", Int J Geriatr Psychiatry, 19, pp.58~67 (2004)
- Maelicke A, "Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease", Biol Psychiatry, 49, pp.279~288 (2001)
- Albuquerque EX, "Modulation of nicotinic receptor activity in the central nervous system:a novel approach to the treatment of Alzheimer disease", Alzheimer Dis Assoc Disord, 15(Suppl 1), pp.S19~S25 (2001)
- Bodick NC, "Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease", Arch Neurol, 54, pp.465~473 (1997)
- Schilstrom B, "Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors", Neuropsychopharmacology, 32, pp.43~53 (2007)